Allergic inflammation in the unified airway: Start with the nose

Thorax

Volumn 55, Issue 10, 2000, Pages 878-881

  Lipworth, Brian J ^a   White, Paul S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; LORATADINE; MONTELUKAST; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; BRONCHUS HYPERREACTIVITY; COMPUTER ASSISTED TOMOGRAPHY; FIBEROPTIC BRONCHOSCOPY; NOSE; NOSE POLYP; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

ADMINISTRATION, TOPICAL; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; DIAGNOSTIC TECHNIQUES AND PROCEDURES; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; RHINITIS, ALLERGIC, PERENNIAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033802297     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.10.878     Document Type: Review

References (36)

1. 1 Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781-6.
2. 2 Chanez P, Vignola AN, Vic P, et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med 1999; 159: 588-95.
3. 3 Casale TB, Lass SC. Immunobiology of asthma and rhinitis: pathogenic factors and therapeutic options. Am J Respir Crit Care Med 1999; 160: 1778-87.
4. 4 Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc 1996; 17: 231-6.
5. 5 Greiff L, Andersson N, Svensson C, et al. Demonstration of bronchial eosinophil activity in seasonal allergic rhinitis by induced plasma exudation combined with induced sputum. Thorax 1999; 54: 33-6.
6. 6 Foresi A, Leone C, Pelucchi A, et al. Eosinophils mast cells and basophils in induced sputum from patients with seasonal allergic rhinitis and perennial asthma: relationship to methacholine responsiveness. J Allergy Clin Immunol 1999; 100: 58-64.
7. 7 Henriksen AA, Sue-Chu M, Holmen TL, et al. Exhaled and nasal NO levels in allergic rhinitis: relation to sensitisation, pollen season and bronchial hyperresponsiveness. Eur Respir J 1999; 13: 301-6.
8. 8 Lamblin C, Gosset P, Salez F, et al. Eosinophilic airway inflammation in nasal polyposis. J Allergy Clin Immunol 1999; 104: 85-92.
9. 9 Reid C, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma symptoms. J Allergy Clin Immunol 1988; 81: 1042-7.
10. 10 Henrikesen JM, Wenzel A. Effect of intranasal administered corticosteroid (budesonide) on nasal obstruction, mouth breathing and asthma. Am Rev Respir Dis 1984; 130: 1014-8.
11. 11 Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate 200 μg reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98: 274-82.
12. 12 Corren J, Adenoff AD, Buchmeier A, et al. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90: 250-6.
13. 13 Wood RA, Eggleston PA. The effects of intranasal steroids on nasal and pulmonary responses to cat exposure. Am J Respir Crit Care Med 1995; 151: 315-20.
14. 14 Aubier N, Levey J, Clerici C, Neukirch F, et al. Different effects of nasal and bronchial glucocorticoid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1992; 146: 122-6.
15. 15 Durham SR, Walker SM, Varga EM, et al. Long term clinic efficacy of grass pollen immunotherapy. N Engl J Med 1999; 341: 468-75.
16. 16 Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma. J Allergy Clin Immunol 2000; 105: 559-74.
17. 17 Woodcock A, Cuslovic A. Avoiding exposure to indoor allergens. BMJ 1998; 316: 1075-8.
18. 18 Van Cauwenberge D, Bachert C, Passalacqua G, et al. Consensus statement of the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55: 116-34.
19. 19 British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London, et al. The British guidelines in asthma management: 1995 review and position statement. Thorax 1997; 52: S1-21.
20. 1-receptor antagonists) therapy useful in clinical asthma? Clin Exp Allergy 1999; 29(Suppl 3): 98-104.
21. 21 Howarth PH, Stern MA, Roi L, et al. Double blind, placebo controlled study comparing the efficacy and safety of fexofenadinc hydrochloride (120 ng and 180ng once daily) and cetirizine in seasonal rhinitis. J Allergy Clin Immunol 1999; 104: 927-33.
22. 22 McNeely W, Wiseman LR. Intranasal azelastine - a review of its efficacy in the management of allergic rhinitis. Drugs 1998; 56: 91-114.
23. 23 Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-63.
24. 24 Pullerits T, Praks L, Skoogh BE, et al. Randomised placebo control study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999; 159: 1814-8.
25. 25 Dempsey OJ, Wilson AM, Sims EJ, et al. A comparison of once daily topical budesonide and oral montelukasi in seasonal allergic rhinitis and asthma. Eur Respir J 1999; 14(Suppl 30): 530S.
26. 26 Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratidine as treatment for seasonal allergic rhinitis: a randomised, placebo controlled clinical trial. J Allergy Clin Immunol 2000; 105: 917-22.
27. 27 Reicin AS, Weinstein SF, White R, et al. Montelukast plus loratidine compared to montelukast alone provides additional benefit in the treatment of chronic asthma. Am J Respir Crit Care Med 1998; 157: A416.
28. 28 Wilson A, Dempsey OJ, Sims EJ, et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000; 30: 833-8.
29. 29 Wilson AM, Orr LC, Sims EJ, et al. Anti-asthmatic effects of mediator blockade versus topical corticosieroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000 (in press).
30. 30 Wilson A, Sims E, Coutie W, et al. Domiciliary nasal flow is a better marker of treatment response than rhinomanometry or acoustic rhinometry in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 2000; 105 (Part 2): S204.
31. 31 Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2000 (in press).
32. 32 Havas TE, Motheby JA, Gullane PJ. Prevalence of incidental abnormalities on computed tomographic scans of the paranasal sinuses. Arch Otolaryngol Head Neck Surg 1988; 114 :856-69.
33. 33 Bolger WE, Butzin CA, Parsons DS. Paranasal sinus bony anatomic variations and mucosal abnormalities: CT analysis for endoscopic sinus surgery. Laryngoscope 1991; 101: 56-64.
34. 34 Zinreich SJ, Kennedy DW, Rosenbaum AE, et al. Paranasal sinuses CT imaging requirements for endoscopic sinus surgery. Radiology 1987; 163: 769-75.
35. 35 East CA, Annis JAD. Preoperative CT scanning for endoscopie sinus surgery: a rational approach. Clin Otolaryngol 1992; 17: 60-6.
36. 36 White PS, Maclennan AC, Connolly AAP, et al. Analysis of CT scanning referrals for chronic rhinosinusitis. J Laryngol Otol 1996; 110: 641-3.